TTS

TTS, or Tumor-Targeted Superantigen (TTS) is a unique technology designed to paint a tumor with bacterial determinants to make it easily identifiable to the immune system. NeoTX’s lead TTS molecule, naptumomab estafenatox (NAP), is currently being evaluated in a Phase II clinical trial for patients who failed both immunotherapy and chemotherapy in Non-Small Cell Lung Cancer (NSCLC). This is a very large market (~$12Bn) with no effective treatment options and little competition due to the difficulty in treating these patients. To date, the trial has demonstrated impressive response and disease control rates in evaluable patients. The trial should complete enrollment during 2023, and if successful, may lead to a registrational trial with potential approval in 2027.

• TTS Coats tumor with superantigen bacteria molecule to make it easy for the immune system to identify and eliminate the tumor.
• TTS triggers an organic immune response which drives deep, long lasting tumor control.
• Teaches the body to heal itself by restarting the patient’s own natural immune response against the tumor.
• TTS may enhance the efficacy of all three major anticancer modalities: Chemotherapy, Immunotherapy and CAR T.
• Phase 1 study showed acceptable safety in combination with checkpoint inhibitor immunotherapy and produced four remarkable responses in patients who typically do not respond to any treatment.
• A follow-up international study is planned in esophageal cancer, with top US centers asking to particiapate in the trial.
• A phase 2 study in lung cancer in combination with chemotherapy is currently enrolling for patients who failed traditional immunotherapy and chemotherapy.
  • The trial is around 70% enrolled and about 50% of the patients are currently evaluable for response.
  • Our results to date show high objective response and disease control rates compared to that expected with chemotherapy alone.
  • This patient population represents a $12Bn market with high unmet medical need.
  • The ongoing trial will complete enrollment in 2023.
  • The study could lead to a registrational trial in which the drug could be granted marketing approval.
• An investigator sponsored trial in combination with CAR T is currently being evaluated.

ARROW

Arrow is a Computer-Aided Drug Discovery (CADD) platform (operated through NeoTX's subsidiary InterX). Three Nobel Prize-winning scientists, Roger Kornberg (2006), Michael Levitt (2013), and Arieh Warshel (2013) are actively involved in its development.

Of the many CADD platforms developed none of them have the accuracy of measurement. Lack of accuracy translates into a need to iteratively chemically synthesize potential molecules and test them in the lab, which is a time consuming process. Due to this process, CADD assisted drug discovery can require 3-5 years. Arrow is the only technology that offers measurement accuracy in its simulation, obviating the need for much of the synthesis and testing. Having measurement accuracy in simulations could potentially accelerate the drug discovery process to under a year. In addition, the high accuracy of Arrow simulations can suggest improvements for existing drugs, a development pathway with inherently less risk than starting from scratch. For Big pharma, having a technology that can significantly decrease development timelines is not something that they would like to have, but something that they will need to have to stay competitive.

Because Arrow is able to accurately predict the interaction between any two or more molecules, This technology will be transformative in almost a limitless number of applications that can positively impact society. For example, Arrow can be used to make better electric batteries for electric cars and medical devices. No chemical experiments will need to be done until the final solution is reached. In addition, it can be useful for producing better and cheaper air and water filtration devices, so necessary in many regions in the world for improved health.

• Arrow technology is the creation of Nobel laureate Michael Levitt (2013 winner for simulation of biological molecules). Prof. Levitt is one of three Nobel laureates actively involved in Arrow development.
• Arrow simulates molecular interactions based solely on the laws of quantum mechanics without employing approximation-based Artificial Intelligence.
• Management believes that Arrow is the only reliable, accurate simulator which doesn't require training sets to arrive at a solution.
• Arrow has reached POC in systems that until now have been impossible to simulate and gave the same results as actual measurement.
• The accuracy of these simulations can potentially result in the reduction of years of traditional computer drug discovery due to a decrease in the number of molecules that needed to be synthesized and tested.
• NeoTX is exploiting the technology to develop potent KRAS mutant inhibitors and other oncology drugs to broaden our pipeline.
• The Arrow technology is not limited to biotechnology and could possibly be applied to electric car batteries, water filtration devices and even nuclear reactions.